Kalbe Farma Maintains Optimism for 2026 Business Prospects

Strategic Focus on Innovation and Expansion

PT Kalbe Farma Tbk (KLBF), a leading Indonesian healthcare company, remains optimistic about its business prospects for 2026. The company plans to continue various growth initiatives across its diverse business segments, including prescription drugs, health products, nutrition, and distribution & logistics. According to Hari Nugroho, Head of External & Stakeholders Relation at Kalbe Farma, the company is preparing for positive growth in 2026 through comprehensive business strategies and initiatives.

Addressing Global Challenges

Despite ongoing global challenges that could potentially impact the business environment, Kalbe Farma is confident in its ability to navigate these uncertainties. The company is maintaining its focus on innovation and strengthening partnerships as key drivers of growth. This strategic approach is expected to help Kalbe Farma capitalize on emerging opportunities in the healthcare sector.

Long-term Growth Opportunities

The increasing demand for healthcare products and services in Indonesia presents a significant long-term growth opportunity for Kalbe Farma. The company's comprehensive portfolio, which spans various aspects of healthcare, positions it well to benefit from this trend. By continuing to innovate and expand its offerings, Kalbe Farma is well-placed to achieve sustained growth in the coming years.